Results 1 to 10 of about 15,238,642 (306)

Chimeric Antigen Receptor-T Cell Therapy [PDF]

HemaSphere, 2018
. Chimeric antigen receptor (CAR)-T cell therapy is a new class of cellular immunotherapies that involves ex vivo genetic modification of T cells to incorporate an engineered CAR.
Jochen Buechner, Marie José Kersten, Miriam Fuchs, Florence Salmon, Ulrich Jäger   +4 more
doaj   +3 more sources

Chimeric Antigen Receptor T-Cell Revolution Remodeling Immunity to Conquer Autoimmune Disease [PDF]

Research
Chimeric antigen receptor T (CAR-T) cell therapy, a groundbreaking technology in tumor immunotherapy, has demonstrated unprecedented potential in the field of autoimmune diseases in recent years.
Wenxia Shao, Jiayu Liu, Ming Sun, Daojun Yu   +3 more
doaj   +2 more sources

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis

Cells, 2023
Chimeric Antigen Receptor (CAR) T-cell therapy is a promising treatment option for patients suffering from B-cell- and plasma cell-derived hematologic malignancies and is being adapted for the treatment of solid cancers. However, CAR T is associated with
Bryanna Reinhardt, Patrick Lee, Joshua P. Sasine   +2 more
doaj   +3 more sources

Chimeric antigen receptor T cell

Indian Journal of Pharmacology, 2022
During present decade, targeted drug therapy has been the epitome for treatment of cancer. Drugs like Imatinib, a tyrosine kinase receptor inhibitor and Trastuzumab, an human epidermal growth factor receptor-2/neu inhibitor, has been developed and accepted widely for management of chronic myeloid leukaemia and breast cancer ...
Singh, Surjit, Khasbage, Sameer, Kaur, Rimple Jeet, Sidhu, Jaspreet Kaur, Bhandari, Bharti   +4 more
openaire   +2 more sources

[Chimeric antigen receptor T cells].

Bulletin du cancer, 2021
Chimeric antigen receptor T-cell (CAR T-cells) therapies which are genetically modified T lymphocyte targeting tumor antigens have modified therapeutic landscape in hematology. Aggressive B cells lymphoma are currently treated in daily practice with anti-CD19 CAR T.
Bories, Pierre, Ysebaert, Loïc
openaire   +2 more sources

Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure

Transplantation and Cellular Therapy, 2023
Outcomes for post-chimeric antigen receptor (CAR) T cell therapy (CART) relapse are poor. The utilization of a unique CAR T cell construct for post-CART failure is increasing, but this approach is not well described. In this study, with CART-A the first unique CAR T cell construct received and CART-B the second, the primary objective was to ...
Elizabeth M. Holland, Bonnie Yates, Seth M. Steinberg, Constance M. Yuan, Hao-Wei Wang, Colleen Annesley, Haneen Shalabi, David Stroncek, Terry J. Fry, Joerg Krueger, Elad Jacoby, Emily Hsieh, Deepa Bhojwani, Rebecca A. Gardner, Shannon L. Maude, Nirali N. Shah   +15 more
openaire   +2 more sources

CAR-T cell therapy for hematological malignancies: History, status and promise

Heliyon, 2023
For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis.
Chao Wang, Jianpeng Wang, Shusheng Che, Hai Zhao   +3 more
doaj   +1 more source

Novel Use of Extracorporeal Blood Purification for Treatment of Severe, Refractory Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy—A Case Report

Critical Care Explorations, 2021
BACKGROUND:. Chimeric antigen receptor T-cell therapies (CAR-T) are transforming the treatment of B-cell leukemias and lymphomas. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome represent common, potentially life ...
Kai Singbartl, MD, MPH, Allison Rosenthal, DO, Jose Leis, MD, PhD, Bhavesh Patel, MD, Ayan Sen, MD, MSc   +4 more
doaj   +1 more source

T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies

Nature Communications, 2022
Healthy T cells are polyclonal, while malignant T cells are developing via clonal expansion. Here authors show that T cell tumours could be eradicated by chimeric antigen receptor T cells targeting the T cell receptor (TCR) β-chain that is specific to ...
Fanlin Li, Huihui Zhang, Wanting Wang, Puyuan Yang, Yue Huang, Junshi Zhang, Yaping Yan, Yuan Wang, Xizhong Ding, Jie Liang, Xinyue Qi, Min Li, Ping Han, Xiaoqing Zhang, Xin Wang, Jiang Cao, Yang-Xin Fu, Xuanming Yang   +17 more
doaj   +1 more source

Chimeric Antigen Receptors for T-Cell Malignancies [PDF]

Frontiers in Oncology, 2019
Development of chimeric antigen receptor (CAR)-modified T cells for the treatment of T-lineage leukemia and lymphoma has encountered several unique challenges. The most widely expressed tumor antigen targets for malignant T cells are often also expressed on non-malignant T cells.
Lauren D. Scherer, Lauren D. Scherer, Malcolm K. Brenner, Malcolm K. Brenner, Malcolm K. Brenner, Maksim Mamonkin, Maksim Mamonkin, Maksim Mamonkin, Maksim Mamonkin   +8 more
openaire   +3 more sources